Literature DB >> 9373104

Botulinum toxin management of childhood intermittent exotropia.

R F Spencer1, M G Tucker, R Y Choi, K W McNeer.   

Abstract

OBJECTIVE: Intermittent exotropia is a common form of childhood strabismus that has a late onset and presents a difficult and frustrating management dilemma. Surgical treatments have a high recurrence rate, and multiple surgeries often are required to achieve a desirable motor outcome. This study presents long-term observations on the use of botulinum toxin for the treatment of intermittent exotropia in children.
DESIGN: This study is a nonrandomized, case-controlled study of consecutive pediatric patients who had intermittent exotropia. PARTICIPANTS: Thirty-two neurologically normal children ranging from 3 to 144 months in age were diagnosed with intermittent exotropia with a minimum distance deviation of 15 prism diopters (PD). INTERVENTION: Simultaneous bilateral injections of 2.5 units botulinum toxin type A were made into the lateral rectus muscles with the patient receiving nitrous oxide-ethrane inhalation anesthesia. Patients were observed for 12 to 44 months after the initial injection. MAIN OUTCOME MEASURES: A satisfactory outcome was considered to be stable binocular alignment of the eyes to an orthophoric range of +/-10 PD.
RESULTS: Bilateral lateral rectus muscle injections of botulinum toxin were effective in reducing the mean preinjection deviation of -29 PD to an average exotropic angle of -6 PD. Stable orthophoria (+/-10 PD) was achieved in 22 patients (69%). Overall, male patients required significantly fewer injections than did female patients. All patients between 24 and 56 months of age, irrespective of gender, required only a single bilateral injection to achieve a favorable motor outcome.
CONCLUSIONS: Botulinum toxin is at least as effective as surgical outcomes reported previously for the treatment of intermittent exotropia in children. This treatment method is particularly effective in children between 2 and 4.5 years of age irrespective of the initial strabismic angle and is not associated with any secondary abnormalities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373104     DOI: 10.1016/s0161-6420(97)30029-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

Review 1.  Interventions for intermittent exotropia.

Authors:  Yi Pang; Lawrence Gnanaraj; Jessica Gayleard; Genie Han; Sarah R Hatt
Journal:  Cochrane Database Syst Rev       Date:  2021-09-13

Review 2.  Non-surgical Management Options of Intermittent Exotropia: A Literature Review.

Authors:  Samira Heydarian; Hassan Hashemi; Ebrahim Jafarzadehpour; Amin Ostadi; Abbasali Yekta; Mohamadreza Aghamirsalim; Nooshin Dadbin; Hadi Ostadimoghaddam; Fahimeh Khoshhal; Mehdi Khabazkhoob
Journal:  J Curr Ophthalmol       Date:  2020-07-04

Review 3.  Interventions for intermittent exotropia.

Authors:  Sarah R Hatt; Lawrence Gnanaraj
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

Review 4.  Botulinum toxin for the treatment of strabismus.

Authors:  Fiona J Rowe; Carmel P Noonan
Journal:  Cochrane Database Syst Rev       Date:  2017-03-02

Review 5.  The role of drug treatment in children with strabismus and amblyopia.

Authors:  K I Chatzistefanou; M D Mills
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.930

6.  Treatment of acute acquired concomitant esotropia.

Authors:  Minghua Shi; Yuanxiang Zhou; Aijiao Qin; Jing Cheng; Hongxing Ren
Journal:  BMC Ophthalmol       Date:  2021-01-06       Impact factor: 2.209

7.  Efficacy of Botulinum Toxin Injection in Exotropia Treatment.

Authors:  Seham S Al Hemaidi; Gorka Sesma; Khabir Ahmad; Ruba Saleh Alghofaili; Raseel A Awad
Journal:  Middle East Afr J Ophthalmol       Date:  2021-12-31

8.  Comparison of Botulinum toxin type A with surgery for the treatment of intermittent exotropia in children.

Authors:  Han Su; Jing Fu; Xiao Wu; Ali Sun; Bowen Zhao; Jie Hong
Journal:  BMC Ophthalmol       Date:  2022-02-04       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.